You are here

Nat Med DOI:10.1038/s41591-018-0168-6

Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.

Publication TypeJournal Article
Year of Publication2018
AuthorsWong, GS, Zhou, J, Bin Liu, J, Wu, Z, Xu, X, Li, T, Xu, D, Schumacher, SE, Puschhof, J, McFarland, J, Zou, C, Dulak, A, Henderson, L, Xu, P, O'Day, E, Rendak, R, Liao, W-L, Cecchi, F, Hembrough, T, Schwartz, S, Szeto, C, Rustgi, AK, Wong, K-K, J Diehl, A, Jensen, K, Graziano, F, Ruzzo, A, Fereshetian, S, Mertins, P, Carr, SA, Beroukhim, R, Nakamura, K, Oki, E, Watanabe, M, Baba, H, Imamura, Y, Catenacci, D, Bass, AJ
JournalNat Med
Date Published2018 Aug 09
ISSN1546-170X
Abstract

In the Supplementary Information originally published with this article, a lane was missing in the β-actin blot in Supplementary Fig. 2. The lane has been added. The error has been corrected in the Supplementary Information associated with this article.

DOI10.1038/s41591-018-0168-6
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/30093730?dopt=Abstract

Alternate JournalNat. Med.
PubMed ID30093730